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Prevention and treatment of venous ulcers in
primary chronic venous insufficiency
Peter Neglen, MD, PhD, on behalf of writing group II of the Pacific Vascular Symposium 6,
Flowood, MissPrimary chronic venous disease (PCVD) is a progres-
sive degenerative condition that usually results in vein wall
weakness, producing valvular incompetence. The disease
most frequently occurs in the superficial veins and presents
as asymptomatic cosmetic varicose veins. PCVD may also
advance to symptomatic stages with pain, edema, skin
changes, or venous ulcerations.
Primary venous reflux can also develop in the deep and
perforating veins. PCVD may also include a symptomatic
obstructive element when a nonthrombotic iliac vein lesion
(NIVL) is present. PCVD is defined by the basic CEAP
classification as: C2-6 Ep As,d,p Po,r.
1 The letter p (primary)
refers to nonthrombotic, noncongenital etiology. The pa-
thology is mainly related to deep and/or superficial valve
incompetence creating an axial reflux projecting into the
ulcer area.2 Symptomatic NIVL has previously been de-
scribed as May-Thurner syndrome, Cockett’s, or “iliac vein
compression” syndrome.3,4 The existence of marked iliac
vein compressions (more than 50% obstruction) with or
without intraluminal lesions has been shown to be more
pathogenic than previously thought. In the past, these
lesions have been considered a common finding of little
clinical importance.5 Primary venous insufficiency should
be differentiated from secondary postthrombotic venous
insufficiency because the two conditions differ in patho-
physiology, management, and prognosis. “Hydrostatic”
leg ulcers without venous reflux and/or obstruction (eg, in
morbidly obese patients [C5-6 Es An Pn]) are excluded in
this discussion.6
As early as 1948, the Swedish surgeon Gunnar Bauer
found a group of patients with venous leg ulceration who
had no history of previous deep venous thrombosis (DVT)
but a family history of varicose veins. Descending trans-
femoral venography showed a patent, uniformly wide, deep
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the contrast to descend into the calf veins.7 No postthrom-
botic changes, such as irregular lumen, collaterals, or
poorly identified valve stations, were noted. Bauer’s inter-
pretation was that there was a loss of elasticity in the vein
wall leading to dilatation and subsequent incompetence of
the valve. He termed this condition idiopathic deep vein
incompetence; this condition today is defined as primary
valvular incompetence. Hach et al have later suggested an
additional hypothesis (ie, the deep veins will dilate second-
ary to massive superficial reflux because of “overloading”).8
Treatment of the superficial reflux in these patients may
correct the deep venous reflux. This normalization of ve-
nous flow is frequently seen with segmental primary deep
incompetence, but rarely with axial deep reflux.9-12 Map-
ping of reflux by duplex ultrasound scanning in limbs with
primary or secondary reflux and leg ulceration has shown
that superficial reflux is present in approximately 80% of
limbs, and in half of these limbs it is combined with deep
venous reflux.13-15 The prevalence of significant NIVL in
these patients is not known.
Current evidence suggests that multiple factors may
lead to intrinsic structural and biochemical abnormalities of
the vein wall in PCVD resulting in remodeling of the
venous wall and valvular incompetence in PCVD (see Crit-
ical Issue 2). This process appears to be multicentric; thus,
primary valve incompetence develops simultaneously in
discontinuous vein segments. Valves may not fail in a
progressive descending or ascending uninterrupted order
as previously thought.16
PCVD is widespread in the population and is far more
prevalent than secondary (postthrombotic) disease. It is
responsible for the development of chronic venous insuffi-
ciency (C3-C6) in 20% of the older population. A meta-
analysis comprising 390 ulcer patients with PCVD having
duplex ultrasound scanning revealed superficial incompe-
tence alone and combination of deep and superficial reflux
in 44% and 43% of ulcerated limbs, respectively.17,18 The
clinical expression of PCVD is indistinguishable from that
of postthrombotic disease in its late stages, but the
medical and surgical treatment considerations are dis-
tinctly different.
We have identified four critical issues concerning pri-
mary chronic venous disease, which are central in the
endeavor to decrease the prevalence of venous leg ulcers by
50% at 10 years.
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Standardization of diagnostic testing (especially
ultrasound scanning) for chronic venous disease and
criteria for interpretation of the results
Background. Studies on how to identify patients with
PCVD that will progress to ulceration do not exist. It has
been shown to be important to correct the underlying
pathology in patients with established venous ulcer disease
to prevent recurrence.19 However, there is no standard for
evaluation of reflux/obstruction and changes of the micro-
circulation in CVD by Intersocietal Commission for Ac-
creditation of Vascular Laboratories (ICAVL) in the
United States. Standardization is vital to move forward
because of its importance to direct treatment in clinical
practice as well as to perform research. There is also a lack of
basic information on ambulatory venous pressure and he-
modynamic changes in the microcirculation.20
Evidence. Many laboratories have developed proto-
cols for evaluating reflux and obstruction in the lower
limbs, but there is no standardization of method and
interpretation.
Discussion highlights. Duplex ultrasound scanning
(DUS) is the most common and available test, and, there-
fore, central in evaluation of CVD, regardless of etiology, in
clinical practice. Standardizing the method of scanning and
the interpretation of the results would quickly have a major
impact on CVD treatment. Primary care physicians would
learn when to consult a vascular specialist for assessment
and possible intervention. Since DUS of the ilio-caval vein
segment is frequently difficult to perform, additional imag-
ing studies may be needed to detect iliofemoral venous
outflow obstruction as per institutional preference (eg,
transfemoral contrast venography, magnetic resonance
venography, computed tomography venography, or intra-
vascular ultrasonography [IVUS]). There are no standard
methods of quantification of hemodynamically significant
venous outflow obstruction.21 Methods of measuring out-
flow resistance also need to be developed.
There are no known hemodynamic methods to identify
which patient with PCVD and limbs with C-class 2 to 4 will
progress to develop leg ulcers. To achieve this goal, other
hemodynamic tests in addition to ultrasound scanning
should be utilized. Duplex ultrasound scanning parameters
of interest would be the anatomic extent and distribution of
reflux and obstruction (such as the system proposed by
Hach),22 and quantification of reflux by peak volume re-
flux, peak reflux, etc.23 Hemodynamic tests, such as pleth-
ysmography (air plethysmography, foot volumetry, or
strain-gauge)24 and laser Doppler measurements, such
as veno-arterial response (VAR) and vasomotor activity
(VA),25,26 need further evaluation. When these hemody-
namic tests are used, the patients need to be followed with
clinical severity scores (venous clinical severity, segmental
disease, and disability scores or others), which are more
sensitive than C-classification to detect symptomatic pro-
gression.Conclusion. It is necessary to develop first a protocol
for CVD investigation for clinical practice, and then intro-
duce a more sophisticated protocol for longitudinal re-
search of CVD.
Recommendations. Standardize venous duplex stud-
ies for clinical practice and reimbursement in the U.S. by:
1. Establishing a protocol for DUS to detect venous reflux
and obstruction in CVD, regardless of etiology. The
scanning should include the inferior vena cava and iliac
veins as able.
2. Achieving ICAVL approval: For research purposes, it is
important to develop ultrasound measurements, which
identify not only presence but also provide quantifica-
tion of reflux and obstruction. The ultimate goal will be
to assess the contribution of reflux/obstruction in each
system (superficial/deep/perforator) and at various lev-
els (axial/segmental; ilio-femoral/femoro-popliteal) to
the global hemodynamics of the lower limb. This would
enable directed treatment. Additionalmethods of studying
venous hemodynamics and the microcirculation should
also be used in longitudinal studies. With regards to
PCVD, it is essential to identify measurements that
would predict progression of limbs of C-class 2-4 to
active leg ulcers.
Action. The American Venous Forum (AVF) is well
positioned to take the lead and to coordinate with other
societies the development of a clinical protocol for ultra-
sound scanning. Members can be identified with contacts
in ICAVL, and societies of interest could shoulder this
responsibility. This goal should be possible to achieve in a
relatively short time frame (1 year) and reached with
ICAVL approval. This would impact on the overall goal to
achieve reduction of leg ulcer prevalence by 50% in 10
years.
Protocols for research will be performed by individual
institutions or cooperation between interested institutions.
Central to this would be cooperation between members of
AVF and other societies with special interest in evaluation
of the hemodynamics of CVD and vascular laboratories in
general. This task is more challenging. First, the hemody-
namic parameters have to be identified and then applied in
longitudinal studies. The time span is at least 5 years. It is
doubtful that, by this stage, this will have an impact on the
overall goal of the present endeavor.
CRITICAL ISSUE 2
Identification of factors (other than hemodynamic)
that identify patients with PCVD and C-class 2, 3,
and 4 limbs, who are at risk for progression to
C-class 6
Background. There is a lack of information on the
natural history of PCVD. If factors for disease progression
in patients with primary chronic venous disease could be
identified, a modification of these factors, if feasible, may
prevent development of venous ulcer.
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factors look at risk of ulceration regardless of etiology and
not the risk of progression between C-classes in limbs with
PCVD. No validation of risk factors in class progression
exists. However, risk factors for ulcer recurrence (other
than presence of postthrombotic disease) have been iden-
tified and somemay be helpful (eg, residual iliofemoral vein
obstruction; residual deep incompetence, particularly axial
deep reflux; residual or recurrent superficial reflux; and
persistent venous hypertension).27-30
Discussion highlights. There are many proposed
clinical risk factors, which need clarification of their role in
progression of the disease.31 Some of these are age, obesity,
smoking, pregnancy, gender, hypertension, use of hor-
mones, “feeling of swelling,” and occupation. In addition,
clinical signs (eg, corona phlebectatica and other skin
changes) may warrant early intervention to prevent later
ulcer formation. In the Bonn Vein Study I, conducted in
2000, 3072 participants of the general population of the
city of Bonn and two rural townships, aged 18 to 79 years
took part (1350 men, 1722 women).32 Participants were
selected via simple random sampling from the registries of
residents. In a follow-up study (Bonn Vein Study II) 6.6
years later, the same population was investigated again. The
incidence of progress to chronic venous insufficiency (C3-
C6) was approximately 2.0% per year. In a multivariate
analysis, the main risk factors for developing severe stages
(C4-C6) were age, arterial hypertension, and obesity. Fur-
ther, does development of symptoms in limbs with C2 to
C4 signal a risk of progression to ulcer formation? Data-
bases with some of this information are available, but as yet
not published (www.heonline.nhs.uk).24 In the Bonn Vein
Study II, the “feeling of swelling” increased the risk for the
development of CVI significantly (unpublished data).
There are studies showing that mechanical dysfunction
of the calf muscle pump may enhance the development of
leg ulceration.33 It will be important to investigate ankle
range of motion,34 calf muscle pump function, and patient
activity in relation to progression of disease. The data that
are presently available need to be correlated to progression
of the disease.
Genetic factors may also play a role in progression to
advanced chronic venous disease. A relationship between
the C282Y polymorphism in hemochromatosis (HFE
gene) and venous ulceration has been described.35 Gene
polymorphisms and biomarkers that may identify high-risk
patients for progression to ulceration should be investi-
gated (some studies are in progress). Bio-banks for subse-
quent analysis in longitudinal studies need to be estab-
lished. Patients with ulcers have a 2- to 30-times higher
prevalence rate of thrombophilia than the general popula-
tion, despite no previous DVT. Presence of certain throm-
bophilias, such as antithrombin deficiency, may be a risk
factor for ulcer development.36
It would be of value to identify biomarkers signaling an
increased risk of ulcer formation. Most agree that universal
markers such as IL-6 are elevated, but it is uncertainwhether or not they may indicate progression of the
disease.37,38
Most would agree that wall dilation and valve incom-
petence in PCVD is related to venous endothelial dysfunc-
tion. Endothelial cellular injury and activation increase the
expression of inflammatory markers and leukocyte recruit-
ment in varicosities, and venous wall changes are thought
to contribute to the weakening, dilatation, and valve reflux.
Varicose vein patients demonstrate imbalances in the hu-
moral mediators of vasoconstriction and venous dilatation.
Plasma levels of endothelin-1 are increased in those with
varicose veins and rise disproportionately in the response to
venous stasis. Plasma levels of nitric oxide, a potent medi-
ator of vascular relaxation, may also be modulated. Matrix
metalloproteinase (MMP) 2 may also lead to alterations in
the extracellular matrix as well as venous relaxation.Most of
the studies are observational.16,39 The understanding
of the natural history and progression of PCVD remains
incomplete. Current evidence suggests the multifactorial
origin of PCVD, leading to tissue remodeling of the venous
wall with changes in the microcirculation and dermis. More
studies to identify markers of endothelial dysfunction of
prognostic value are necessary.
Are there differences in skin type/metabolism/race
that may place patients at an increased risk of ulceration?
Some studies indicate this.24,40-42
Do quality of life (QoL) measurements correlate with
disease severity (overall, yes),43,44 and in turn correlate with
those patients that are at increased risk for disease progres-
sion (presently no evidence)? Can QoL assessment be used
as a surrogate marker for patients at risk for disease progres-
sion? Currently there is no evidence that QoL can be used
to identify who will progress since QoL is not directly
related to venous incompetence.
Conclusions. There is a need for additional studies on
the natural history of PCVD and factors responsible for
disease progression to ulcer formation, such as clinical,
mechanical, humoral, genetic, and endothelial risk factors.
Recommendations. To perform longitudinal studies
evaluating factors responsible for disease progression. In
addition, identify genetic and humoral mediators of endo-
thelial dysfunction, which are present in limbs with PCVD
and disease progression.
Actions. Studies on clinical risk factors and clinical
signs associated with progress of the disease are already in
place, and analysis needs to be finalized (see above Bonn
Vein Study II). It is possible to reach this goal within 1 year.
Further studies regarding other factors have to be initiated.
It will probably be difficult to perform longitudinal studies
on the influence of these factors on disease progression. An
alternative way is to find unique features in limbs with
already established ulcers (C6) as compared with limbs with
lower severity venous disease, C2 to C4. Modification of
some of these risk factors may, however, not be possible. It
may not have an impact on ulcer prevalence in 10 years.
There is a need to obtain more information on the impact
of progression on quality of life by following patients in
longitudinal studies.
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Identification of treatments, which may prevent
progression in patients with C2, C3, or C4 limbs to
formation of leg ulcers (C6)
Background. By intervening at early stages of PCVD,
and so preventing progression of the disease, would lower
the prevalence of ulcers within 10 years.
Evidence. No study exists on the efficacy of compres-
sion therapy, pharmacotherapy, or endovenous/open in-
terventions on prevention of progression of PCVD.
Discussion highlights. There are older studies giving
the prevalence of venous ulceration, although most reports
have deficiencies, and regional numbers are difficult to
apply to the general population.45,46 There is a need to
establish new point prevalence rates of limbs with venous
ulceration, since currently patients with venous disease have
generally better care reducing the rate of ulcer incidence. It
is possible that even if we add nothing to current practice,
the ulcer prevalence will be reduced by 50% in 10 years. It
may be of value to compare snapshots of venous ulcer
prevalence today with 5 years ago as a baseline.
External compression. External support will result in
clinical improvement and help control swelling. There is
evidence that stockings help alleviate symptoms of C2
disease in pregnant women.47 A systematic review of 39
randomized trials concluded that ulcer healing rates are
increased when compression therapy is used compared with
no compression therapy.48 There is, however, no report
evaluating their effect on progression of PCVD. The main
problem when studying efficacy of compression devices,
including compression stockings, is how to ensure and
track patient compliance of usage. In addition, it is not
known whether or not all patients with C2 to C4 limbs
should use compression therapy. If only symptomatic pa-
tients are to use compression, the assumption is made that
only patients with symptomatic disease are at risk for pro-
gression to leg ulcer. That may not necessarily be true. The
types of stocking or other devices and the adequate pressure
gradient have also to be assessed to optimize compression
therapy in PCVD. Compression therapy following acute
DVT has been shown to reduce the incidence of subse-
quent postthrombotic syndrome and progression to ulcer
formation.49 The results are not transferable to PCVD, but
show that prospective comparative studies with and with-
out compression therapy should be feasible in patients with
marked C2 disease.
Drug therapy. There are studies that show pentoxifyl-
line to have a beneficial effect on ulcer healing with or
without adjunctive compression therapy.50,51 Although
there is a theoretic possibility that pentoxyfylline or veno-
active drugs and statins may prevent progression, no sup-
porting studies exist.
Endovenous procedures including foam sclerother-
apy or open surgery. It is important to decide in what
sequence to treat primary vein obstruction and reflux and
which vein segments to treat. Most agree to control super-
ficial vein reflux first, even in the presence of deep veinreflux. Significant outflow obstruction by NIVL should
probably be treated early. There are no data to support that
treating perforators in limbs with C2 or C3 disease will have
an effect on progression. It would be important to assess
whether or not treatment of perforators, deep valve insuf-
ficiency, or venous outflow obstruction may prevent pro-
gression in limbs with C4 disease to C6.
Conclusions. Substantial need formore information if
early intervention with compression therapy, drug therapy,
or surgery will prevent progression to ulcer formation.
Recommendations. Studies have to be performed.
There may be substantial difficulty to perform this ade-
quately, since it will be difficult not to intervene in symp-
tomatic patients with clinical severity classes below C6.
Actions. With regard to current point prevalence, it
may be of value to study Medicare data today and compare
with data obtained from 2000 or 2005, to reveal important
trends. Data from theOlmsted County epidemiology study
showed that the overall incidence of venous ulcers in pa-
tients older than 45 years of age are estimated at 3.5 per
thousand per year, and the incidence of venous ulcers
remains unchanged over 20 years, between 1970 and
1990.52 This epidemiologic study continues and may soon
give us an answer on current trends. Adequate longitudinal
studies on impact of intervention may not be possible.
CRITICAL ISSUE 4
Calculate the number of symptomatic C2, C3, and
C4 patients needed to treat to prevent an ulcer
Background. It is necessary to find out how many
symptomatic or asymptomatic patients at risk to develop
venous ulcer are necessary to treat to avoid one leg ulcer.
This is a critical issue since it will be necessary to justify the
cost of preventive treatment to payers.
Evidence. Since there is a lack of information to iden-
tify the patient at risk, there are also sparse data on preven-
tion. No appropriate data are available since information on
early intervention and progression of PCVD largely does
not exist. There are some extrapolations made from a
Swedish study suggesting that 100 symptomatic patients
with varicose veins have to be operated on to prevent one
ulcer; however, this number decreases to 10 when limbs
with C4 disease are treated.53
Discussion highlights. It is important to offer best
treatment options for at-risk C2 to C4 patients to optimize
prevention of progression. It is likely that a large number of
patients may be necessary to treat to prevent one ulcer,
whichmay be relatively costly for society. Themost obvious
health care saving is made by avoiding a lengthy and costly
ulcer treatment owing to decreased incidence of leg ulcer
formation.However, it must also be stressed that secondary
gains are achieved. The patients receiving preventive treat-
ment are also likely to experience a substantial improve-
ment of quality of life in addition to ulcer prevention.
Conclusion. Any preventive method has to be related
to the number of patients treated to prevent one leg ulcer.
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fects on the patients need to be assessed.
Recommendations. Based on the outcome of Critical
Issues 1 to 3, it may be possible to acquire the necessary
information to perform cost-benefit analysis.
Actions. This issue is intimately connected with the
solution of Critical Issues 1 to 3. Without having the data
giving the patients at risk, it is impossible to make a cost-
benefit analysis.
CONCLUSION
To summarize, regardless of etiology of venous ulcer-
ations, it is fundamentally necessary to develop first, a
protocol for CVD investigation for clinical practice, and
second, a more sophisticated protocol for longitudinal
research of CVD. The natural history of primary CVD and
factors responsible for disease progression to ulcer forma-
tion, such as clinical, mechanical, humoral, genetic, and
endothelial risk factors must be studied. There is also a lack
of information as to whether or not early intervention by
compression treatment, drug therapy, or ablative interven-
tions will prevent progression to ulcer formation in primary
CVD. Any preventive method has to be related to the
number of patients needed to be treated to prevent one
venous ulcer, owing to the potential socio-economic im-
pact. The associated costs and additional beneficial effects
on the patients’ quality of life need to be assessed.
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